companies that manufacture glp-1 medications Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists The push to make weight-loss
Description
CME INDIA: NoGLP-1 receptor agonists (GLP-1RAs) and tirzepatide are not contraindicated in patients with GERD or hiatus hernia
The high prevalence of comorbidities such as diabetes, visceral obesity, and aging, which contribute to systemic inflammation, plays a pivotal role in the pathogenesis and progression of HFpEF
This risk paralleled the rise in obesity rates, making MASLD a consequence of the Metabolic Syndrome (MetS)
Non-GLP-1 weight loss medications offer alternatives for patients who cannot tolerate GLP-1 agents or require different mechanisms of action
